Vitamin B12 deficiencies
Conditions
Interventions
Trade Name: Hydroxocobalamine
Product Name: Hydroxocobalamine
Pharmaceutical Form: Solution for injection
Sponsors
Rijnstate Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who underwent RYGB Patients who developed a vitamin B12 deficiency postoperatively Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Creatinine> 150 micromol / L Liver enzymes> 2 times the upper limit Previous operations on the gastrointestinal tract (except RYGB) Intercurrerende disease Gastrointestinal disease psychiatric illness known pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Prospective evaluation of the effect of Vitamin B12 tablets (which are available in stores) in comparison with hydroxocobalamine injections for vitamin B12 deficiencies in patients who underwent a Roux-en-Y Gastric Bypass.;Secondary Objective: Not applicable;Primary end point(s): Vitamin B12 deficiencies after 1 year;Timepoint(s) of evaluation of this end point: 3, 6 and 12 months after starting of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): none;Timepoint(s) of evaluation of this end point: none | — |
Countries
Netherlands
Contacts
Public ContactJ. Homan
Rijnstate Hospital
Outcome results
None listed